MX2021006094A - Uso de cannabinoides en el tratamiento de epilepsia. - Google Patents

Uso de cannabinoides en el tratamiento de epilepsia.

Info

Publication number
MX2021006094A
MX2021006094A MX2021006094A MX2021006094A MX2021006094A MX 2021006094 A MX2021006094 A MX 2021006094A MX 2021006094 A MX2021006094 A MX 2021006094A MX 2021006094 A MX2021006094 A MX 2021006094A MX 2021006094 A MX2021006094 A MX 2021006094A
Authority
MX
Mexico
Prior art keywords
cbd
present
extract
epilepsy
treatment
Prior art date
Application number
MX2021006094A
Other languages
English (en)
Inventor
Geoffrey Guy
Volker Knappertz
Original Assignee
Gw Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Res Ltd filed Critical Gw Res Ltd
Publication of MX2021006094A publication Critical patent/MX2021006094A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de cannabidiol (CBD) en el tratamiento de epilepsia que resulta de la mutación del gen GRIN2A. El CBD usado se presenta en forma de un extracto de cannabis altamente purificado, de manera que el CBD está presente en más del 98% del extracto total (p/p) y los demás componentes del extracto están caracterizados. En particular, el cannabinoide tetrahidrocannabinol (THC) está presente en una cantidad del 0.02 al 0.1% (p/p). En una modalidad alternativa, el CBD puede estar en una forma sintética. En su uso, el CBD también puede usarse de forma concomitante con uno o más medicamentos antiepilépticos (AED). El CBD puede estar formulado para ser administrado por separado, secuencial o simultáneamente con uno o más AED o la combinación puede ser proporcionada en una sola forma de dosificación. Cuando el CBD está formulado para su administración por separado, secuencial o simultáneamente, puede suministrarse como un kit o junto con las instrucciones para administrar uno o más componentes de la manera indicada. También puede usarse como único medicamento, es decir, como monoterapia.
MX2021006094A 2018-11-30 2019-11-28 Uso de cannabinoides en el tratamiento de epilepsia. MX2021006094A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1819573.5A GB2580881A (en) 2018-11-30 2018-11-30 Use of cannabinoids in the treatment of epilepsy
PCT/GB2019/053372 WO2020109806A1 (en) 2018-11-30 2019-11-28 Use of cannabinoids in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
MX2021006094A true MX2021006094A (es) 2021-07-06

Family

ID=65024803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006094A MX2021006094A (es) 2018-11-30 2019-11-28 Uso de cannabinoides en el tratamiento de epilepsia.

Country Status (12)

Country Link
US (1) US20220008355A1 (es)
EP (1) EP3886825A1 (es)
JP (1) JP2022510292A (es)
KR (1) KR20210098497A (es)
CN (1) CN113164411A (es)
AU (1) AU2019387553A1 (es)
BR (1) BR112021010405A2 (es)
CA (1) CA3121230A1 (es)
GB (1) GB2580881A (es)
IL (1) IL283372A (es)
MX (1) MX2021006094A (es)
WO (1) WO2020109806A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2581517A (en) * 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
GB2597304A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
GB2597313A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597320A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597318A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597317A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531280A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN116370475A (zh) * 2017-08-31 2023-07-04 武田药品工业株式会社 中枢神经系统病症的治疗
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES

Also Published As

Publication number Publication date
IL283372A (en) 2021-07-29
EP3886825A1 (en) 2021-10-06
KR20210098497A (ko) 2021-08-10
US20220008355A1 (en) 2022-01-13
GB201819573D0 (en) 2019-01-16
BR112021010405A2 (pt) 2021-08-24
CN113164411A (zh) 2021-07-23
GB2580881A (en) 2020-08-05
JP2022510292A (ja) 2022-01-26
WO2020109806A1 (en) 2020-06-04
AU2019387553A1 (en) 2021-06-17
CA3121230A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
da Costa et al. Taxane‐induced neurotoxicity: Pathophysiology and therapeutic perspectives
HRP20201506T1 (hr) Uporaba kanabidiolne kiseline u liječenju epilepsije
MX2020005719A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2021014158A (es) Uso de cannabidiol en el tratamiento de espasmos epilepticos.
MX2019001286A (es) Composicion de cannabis.
MX2021006270A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
CL2019000268A1 (es) Composición de cannabis.
MX2020005147A (es) Uso de cannabinoides en el tratamiento de convulsiones asociadas al sindrome de lennox-gastaut.
CL2020002401A1 (es) Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas.
US20140314757A1 (en) Phytocannabinoids for use in the treatment of breast cancer
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
US11000486B2 (en) Combination of cannabinoids in the treatment of leukaemia
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2021006751A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2021012400A (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos.
MX2021013285A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
MX2022004257A (es) Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
Brucki et al. Cannabinoids in Neurology-position paper from scientific Departments from Brazilian Academy of Neurology